News coverage about Surmodics (NASDAQ:SRDX) has trended somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Surmodics earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.7968121502222 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Surmodics (SRDX) traded up 0.41% during midday trading on Friday, hitting $24.60. The stock had a trading volume of 45,948 shares. The company has a market cap of $322.48 million, a P/E ratio of 53.59 and a beta of 0.88. Surmodics has a one year low of $21.90 and a one year high of $30.75. The stock’s 50-day moving average is $26.93 and its 200-day moving average is $24.78.
Surmodics (NASDAQ:SRDX) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.10. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. The business had revenue of $17.80 million for the quarter, compared to analysts’ expectations of $15.98 million. During the same period in the previous year, the company earned $0.37 earnings per share. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. Equities analysts predict that Surmodics will post $0.27 EPS for the current fiscal year.
A number of equities analysts recently issued reports on the company. Lake Street Capital assumed coverage on Surmodics in a report on Friday, July 14th. They issued a “buy” rating and a $40.00 price objective for the company. BidaskClub lowered Surmodics from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. ValuEngine lowered Surmodics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Aegis assumed coverage on Surmodics in a research note on Tuesday, June 27th. They set a “buy” rating for the company. Finally, Zacks Investment Research lowered Surmodics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Three analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $34.33.
In other Surmodics news, VP Joseph J. Stich sold 1,000 shares of Surmodics stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $25.31, for a total value of $25,310.00. Following the sale, the vice president now owns 40,672 shares of the company’s stock, valued at $1,029,408.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Bryan K. Phillips sold 1,226 shares of Surmodics stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $24.85, for a total transaction of $30,466.10. Following the completion of the sale, the senior vice president now directly owns 29,208 shares in the company, valued at approximately $725,818.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,928 shares of company stock worth $392,469. Insiders own 6.40% of the company’s stock.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.